Pre-transplantation levels of lysine (K)-specific methyltransferase 2A (<i>KMT2A</i>) partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation.

Comparison of clinical outcomes between patients with KMT2A -PTD <0.1% (group 1), ≥0.1% but <1% (group 2), and ≥1% (group 3) before HID HSCT Patients in group 3 had a higher 2-year cumulative incidence of relapse after HID HSCT (36.4%, 95% confidence interval [CI]: 6.3%–66.5%) compared with those in group 1 (7.7%, 95% CI: 0.0%–16.2%) ( P = .016), and showed a trend of higher 2-year cumulative incidence of relapse compared with those in group 2 (7.1%, 95% CI: 0.0%–21.1%) ( P = .091) ( Fig. 3 A ).

also in 53,322 other papers